Levels of control of Chilo partellus stem borer in segregating tropical Bt maize populations in Kenya

In Kenya, stem borers destroy an estimated 400,000 metric tons, or 13.5%, of farmers' annual maize harvest costing about US$80 millions. Bacillus thuringiensis (Bt) maize controls stem borers without harming humans, livestock and the environment and was sown to 140m ha-1 globally in 2009. Two public Bt maize lines of cry1Ab::ubi gene (Event 216 and Event 223) were crossed with two non-Bt maize inbred lines, CML144 and CML159. The efficacy in the control of Chilo partellus stem borers in the parents, F1 and F2:3 successive generations were studied in a biosafety level 2 greenhouse. The Btgene effectively reduced stem borer damage with lower values for number of exit holes, tunneling length, proportion of stalk tunneled, number of larvae and number of pupae than the non Bt-maize and the check cultivars. The F1 generations values for all damage parameters studied were comparable to those for the Bt-maize inbred lines as expected. The F2:3 generations showed a spread of damage parameters from resistant to susceptible. These results suggest that the Cry1A(b) genes in the study was inherited following the Mendelian segregation.Key words: Bt maize, Chilo partellus, Bt -endotoxins, biosafety, greenhouse

Phytosterols from Dombeya torrida (J. F. Gmel.)

Dombeya torrida collected from Kinale forest in Kiambu County, Kenya, was Soxhlet extracted with chloroform and by percolation using a  dichloromethane:methanol mixture. The extracts were fractionated using normal phase silica gel in an open column. Five compounds were isolated namely friedelin, friedelan-3β-ol, α-sitosterol, taraxerol and stigmasterol. This is the first report of isolation of these compounds from Dombeya torrida. The isolated compounds were identified by means of 1H-NMR, 13C-NMR, DEPT, MS and IR analyses.Key words: Dombeya torrida, friedelin, friedelan-3β-ol, β-sitosterol, stigmasterol, taraxerol

Evaluation of stem borer resistance management strategies for Bt maize in Kenya based on alternative host refugia

Stem borers are the major insect pests of maize in Kenya. The use of Bacillus thuringiensis (Bt) technology is an effective way of controlling lepidopteran pests. However, the likelihood of development of resistance to the Bt toxins by the target stem borer species is a concern. Forages, sorghum and maize varieties were evaluated for stem borer preference and survivorship in the laboratory and field in four locations in Kenya to identify suitable species and varieties for refugia. The economics of using the different kinds of refugia was also investigated. Vegetation surveys were conducted in 15 districts of Kenya to quantify the area covered by natural refugia. The field and laboratory trials indicated highest egg production, survivorship and more exit holes in all sorghum and maize varieties and some forages. Sorghum, non-Bt Maize, and improved Napier grass varieties Kakamega 1 and Kakamega 2) should be promoted as refugia species in Kenya. Some species and cultivars were identified as cost-effective, flexible, easily adoptable and compatible with farmers’ common production practices. Refugia cultivar with multiple uses is expected to give higher pay-offs than one with single use. However, for successful management of a refugia strategy, strict stewardship is required from appropriate government or community institutions.Key words: Refugia, cost-benefit analysis, Bt-maize, insect pest resistance management

Testing public Bt maize events for control of stem borers in the first confined field trials in Kenya

Transgenic maize (Zea mays L), developed using modified genes from the bacterium Bacillus thuringiensis (Bt), controls stem borers without observable negative effects to humans, livestock or the environment, and is now sown on 134 million hectares globally. Bt maize could contribute to increasing maize production in Kenya. Nine public Bt maize events of cry1Ab and cry1Ba genes were tested in confined field trials site (CFTs) to assess the control of four major Kenyan stem borer species. Leaf damage rating, number of exit holes and tunnel length were scored in the field evaluations. Leaf area consumed and mortality rates among stem borers were scored in the leaf bioassays in a Biosafety Level II laboratory, located at the Kenya Agricultural Research Institute (KARI), National Agricultural Research Laboratories (NARL). Field evaluations showed that Bt maize controlled Chilo partellus with mean damage scores of 1.2 against 2.7 for the non-Bt CML216 control. Laboratory bioassays showed high control for Eldana saccharina and Sesamia calamistis, with mean larval mortality of 64 and 92%, respectively. However, substantial control was not observed for Busseola fusca. These results showed that Bt maize could control three of the four major stem borers in Kenya with mortality records of 52.7% for B. fusca, 62.3% for E. saccharina and 85.8% for S. calamistis. Additional Bt genes need to be sought and tested for effective stem borer control in all maize growing ecologies in Kenya.Key words: Maize, Bt, stem borers, confined field trials

Quality Performance of Drugs Analyzed in the Drug Analysis and Research Unit (DARU) during the Period 2006-2010

During the period 2006-2010, the Drug Analysis and Research Unit analyzed 583 samples. The samples comprised 50.6% local and 49.4% imported products. Samples were subjected to compendial or in-house specifications. The failure rate was 12.2% for local products and 14.2% for imports.  Antibacterial products recorded the highest failure rate (21.6%) while  anticancers and drugs acting on the gastrointestinal, respiratory and  reproductive systems all passed in the tests performed. The failure rate for antiprotozoals, antimalarials, antifungals, anthelminthics and analgesics was 14.3%, 12.5%, 11.8%, 8.9% and 11.5%, respectively.Key words: DARU, drug product, assay, dissolution, antimicrobial, antimalaria

Enhanced infection prophylaxis reduces mortality in severely immunosuppressed HIV-infected adults and older children initiating antiretroviral therapy in Kenya, Malawi, Uganda and Zimbabwe: the REALITY trial

Meeting abstract FRAB0101LB from 21st International AIDS Conference 18–22 July 2016, Durban, South Africa. Introduction: Mortality from infections is high in the first 6 months of antiretroviral therapy (ART) among HIV‐infected adults and children with advanced disease in sub‐Saharan Africa. Whether an enhanced package of infection prophylaxis at ART initiation would reduce mortality is unknown. Methods: The REALITY 2×2×2 factorial open‐label trial (ISRCTN43622374) randomized ART‐naïve HIV‐infected adults and children >5 years with CD4 <100 cells/mm3. This randomization compared initiating ART with enhanced prophylaxis (continuous cotrimoxazole plus 12 weeks isoniazid/pyridoxine (anti‐tuberculosis) and fluconazole (anti‐cryptococcal/candida), 5 days azithromycin (anti‐bacterial/protozoal) and single‐dose albendazole (anti‐helminth)), versus standard‐of‐care cotrimoxazole. Isoniazid/pyridoxine/cotrimoxazole was formulated as a scored fixed‐dose combination. Two other randomizations investigated 12‐week adjunctive raltegravir or supplementary food. The primary endpoint was 24‐week mortality. Results: 1805 eligible adults (n = 1733; 96.0%) and children/adolescents (n = 72; 4.0%) (median 36 years; 53.2% male) were randomized to enhanced (n = 906) or standard prophylaxis (n = 899) and followed for 48 weeks (3.8% loss‐to‐follow‐up). Median baseline CD4 was 36 cells/mm3 (IQR: 16–62) but 47.3% were WHO Stage 1/2. 80 (8.9%) enhanced versus 108(12.2%) standard prophylaxis died before 24 weeks (adjusted hazard ratio (aHR) = 0.73 (95% CI: 0.54–0.97) p = 0.03; Figure 1) and 98(11.0%) versus 127(14.4%) respectively died before 48 weeks (aHR = 0.75 (0.58–0.98) p = 0.04), with no evidence of interaction with the two other randomizations (p > 0.8). Enhanced prophylaxis significantly reduced incidence of tuberculosis (p = 0.02), cryptococcal disease (p = 0.01), oral/oesophageal candidiasis (p = 0.02), deaths of unknown cause (p = 0.02) and (marginally) hospitalisations (p = 0.06) but not presumed severe bacterial infections (p = 0.38). Serious and grade 4 adverse events were marginally less common with enhanced prophylaxis (p = 0.06). CD4 increases and VL suppression were similar between groups (p > 0.2). Conclusions: Enhanced infection prophylaxis at ART initiation reduces early mortality by 25% among HIV‐infected adults and children with advanced disease. The pill burden did not adversely affect VL suppression. Policy makers should consider adopting and implementing this low‐cost broad infection prevention package which could save 3.3 lives for every 100 individuals treated